Tetrabutylphosphonium is a quaternary phosphonium cation with the formula [P(C4H9)4]+. It is commonly encountered as a salt, such as the tetrafluoroborate ([P(C4H9)4][BF4]), bromide ([P(C4H9)4]Br), or chloride ([P(C4H9)4]Cl) salts. These salts are typically synthesized by reacting tributylphosphine with 1-bromobutane or 1-chlorobutane. Tetrabutylphosphonium salts are used as phase-transfer catalysts, ionic liquids, and precursors to other organophosphorus compounds. They are studied for their applications in organic synthesis, catalysis, and electrochemistry. These compounds have garnered interest due to their unique properties, such as their ability to dissolve a wide range of organic and inorganic compounds, their high thermal stability, and their low volatility. Tetrabutylphosphonium salts are also known to exhibit antimicrobial activity and have been investigated for their potential applications in the development of new antimicrobial agents.'
tetrabutylphosphonium: RN given refers to Br [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 75312 |
| CHEMBL ID | 3306056 |
| SCHEMBL ID | 51248 |
| SCHEMBL ID | 9303473 |
| MeSH ID | M0143421 |
| Synonym |
|---|
| tetrabutylphosphonium |
| tetrabutylphosphanium |
| NCGC00248804-01 |
| NCGC00248804-02 |
| 15853-37-9 |
| phosphonium, tetrabutyl- |
| SCHEMBL51248 |
| 4ne , |
| SCHEMBL9303473 |
| DTXSID0045042 |
| CHEMBL3306056 |
| tetra-n-butylphosphonium |
| tetrabutylphosphonium ion |
| NIJ70MFW91 , |
| tetrabutylphosphonium cation |
| unii-nij70mfw91 |
| J279H , |
| tetrabutyl phosphonium ion |
| tetrabutylphosphine |
| Q27284883 |
| STARBLD0020108 |
| AKOS040754166 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Further investigations revealed the single-application dermal LD50 of tetrabutyl phosphonium chloride (Bu4PCl) (using an ethylene carbonate (EC) vehicle) was 600 mg/kg for male rabbits and 500 mg/kg for female rabbits." | ( Acute dermal toxicity of two quarternary organophosphonium salts in the rabbit. Dunn, BJ; Gad, SC; Nichols, CW, 1982) | 0.26 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "A hydrophobic ion-pairing (HIP) concept considering the high dissociation property of alendronate was used as a strategy to improve the bioavailability of alendronate." | ( Studies on the formation of hydrophobic ion-pairing complex of alendronate. Cho, CW; Kwon, HH; Lee, JM; Shin, SC; You, SK, 2009) | 0.35 |
| "Poor water solubility of active pharmaceutical ingredients (API) is a major challenge in drug development impairing bioavailability and therapeutic benefit." | ( Transformation of acidic poorly water soluble drugs into ionic liquids. Balk, A; Galli, B; Holzgrabe, U; Meinel, L; Widmer, T; Wiest, J, 2015) | 0.42 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.49) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||